



Best Available Copy

GP/1644
FG0810 US

RECEIVED

SEP 12 2001

TECH CENTER 1600/2900

P#13

Certificate of mailing under 37 C.F.R. 1.8

hereby certify that this correspondence is being deposited with the United States Patent and Trademark Office in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on 6 September 2001

By: Carolyn C. Caires

Signed: Carolyn C. Caires

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Riser and DeNichilo

U. S. Serial No.: 09/392,024

Filed: 8 September 1999

Examiner: P. Nolan

Title: METHODS FOR DETECTING,
PREVENTING, AND TREATING
RENAL DISORDERS BY
MODULATING, REGULATING, AND
INHIBITING CONNECTIVE TISSUE
GROWTH FACTOR

Group Art Unit: 1644

Attorney Docket No.: FG0810 US

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97(c)

Sir:

Pursuant to 37 C.F.R. 1.56, 1.97, and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants" (PTO Form 1449). Applicants reserve the right to antedate any reference in accordance with standard procedure.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the present application. In addition, this submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI or other report included on the attached list may not have an accurate date for prior art

purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings. Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the PTO Form 1449 be returned to Applicants.


Please charge FibroGen, Inc. Deposit Account No. 50-0811 the \$180.00 fee due for consideration of this communication under 37 C.F.R. 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to FibroGen, Inc. Deposit Account No. 50-0811. A duplicate copy of this correspondence is included for account charging purposes.

If there are any questions regarding this communication, please call the undersigned at 650-866-7200.

Date:

6 September 01

Respectfully submitted,



Leanne C. Price
Reg. No. 42,090

FibroGen, Inc.
225 Gateway Boulevard
South San Francisco CA 94080
Main: 650-866-7200
Facsimile: 650-866-7292